Second Sight Medical Products, Inc. (EYES) is a big mover this pre-market session, as its shares are up nearly 19%. The surge came after the company, a developer of implantable visual prosthetics to restore functional vision to blind patients, announced the first successful implant of a mechanical model of the Orion(TM) I Visual Cortical Prosthesis (“Orion I”) in an animal study.
“This is a major milestone not only for the Company but, more importantly, those affected by virtually all forms of blindness,” said in a statement Robert Greenberg, M.D., Ph.D., President and CEO of Second Sight. “Following the success of Argus II in patients with Retinitis Pigmentosa, we are looking forward to extending the hope of restoring some useful vision to nearly all blind individuals with the Orion I.”
EYES shares recently gained $2.33 to $14.95. In the past 52 weeks, shares of Sylmar, California-based firm have traded between a low of $8.05 and a high of $24.02. Shares are down 36.81% year-over-year ; up 23.00% year-to-date.